Publications by authors named "Kaiyan Su"
Article Synopsis
- This research explored the combination of Cadonilimab, a bi-specific antibody, and Lenvatinib, a tyrosine kinase inhibitor, as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC).
- The study involved 29 patients and found a 37.9% objective response rate and 82.8% disease control rate, with a median progression-free survival of 8.1 months.
- While most patients experienced adverse events, primarily mild to moderate, the results suggest this combination could be a promising new treatment option for advanced HCC.
Small molecule activates citrullination through targeting PAD2.
Philos Trans R Soc Lond B Biol Sci
November 2023
Citrullination is a post-translational modification catalysed by peptidyl arginine deiminase (PAD) enzymes, and dysregulation of protein citrullination is involved in various pathological disorders. During the past decade, a panel of citrullination inhibitors has been developed, while small molecules activating citrullination have rarely been reported so far. In this study, we screened citrullination activator using an antibody against citrullinated histone H3 (cit-H3), and a natural compound demethoxycurcumin (DMC) significantly activated citrullination.
View Article and Find Full Text PDFMusashi-2 (MSI2) is an evolutionally conserved RNA-binding protein and recently considered as an attractive therapeutic target in a wide spectrum of malignancies. However, MSI2-engaged mRNAs are not well profiled, and no MSI2-dependent antagonist is available so far. In the study, we created MSI2 knockout cancer cells and demonstrated that MSI2 is required for the survival of colorectal cancer HCT116 cells but not non-small cell lung cancer A549 cells.
View Article and Find Full Text PDF